文献速递心力衰竭与心肌病心律失常

持久性左心室辅助装置患者的左心室恢复与结局:EUROMACS注册研究

Left ventricular recovery and outcomes in patients with a durable left ventricular assist device: the EUROMACS registry.
PubMed 文献 · Eur Heart J · 2026-07-09

该研究基于欧洲机械循环支持患者注册登记(EUROMACS),纳入1550例有基线和植入后左心室射血分数(LVEF)数据的左心室辅助装置(LVAD)患者,评估左心室恢复的患病率、预测因素及临床影响。左心室恢复多发生在植入后第一年内,4年时无恢复、轻度、中等和完全恢复的边际概率分别为51%、41%、8%和1%。随访期间LVEF每升高10%与全因死亡瞬时风险降低14%相关,且1年时LVEF恢复程度越高,主要不良心血管事件累积发生率越低。

要点

  • LVAD植入后左心室恢复多发生在第一年内,4年完全恢复概率仅1%。
  • INTERMACS 2-4级较1级与任何左心室恢复风险降低相关。
  • 随访LVEF每升高10%与全因死亡瞬时风险降低14%相关。

核心结论

  • 左心室恢复多发生在LVAD植入后第一年内,且与更好的临床结局相关。
  • 肾素-血管紧张素系统抑制剂使用与任何及中等/完全左心室恢复相关。

研究设计与样本

  • 多中心欧洲注册研究(EUROMACS),纳入至少有一次基线和LVAD植入后LVEF测量的患者1550例,中位年龄57(48-64)岁。
  • 左心室恢复分类:无恢复(LVEF增加<5%)、轻度(LVEF增加5%-15%且峰值LVEF<50%)、中等(LVEF增加>15%且峰值LVEF<50%)、完全(LVEF增加≥5%且峰值LVEF≥50%)。

主要发现

  • 4年时无、轻度、中等和完全恢复的边际概率分别为51%(95%CI 48-54%)、41%(95%CI 38-43%)、8%(95%CI 7-9%)和1%(95%CI 0-1%)。
  • 肾素-血管紧张素系统抑制剂使用与任何左心室恢复风险升高相关(HR 1.17;95%CI 1.00-1.37)。

临床怎么用

  • LVAD患者应关注第一年内左心室恢复的评估,恢复程度与更好的临床结局相关。
  • INTERMACS分级较低的患者可能更易实现左心室恢复,肾素-血管紧张素系统抑制剂使用与恢复相关。

局限性

  • 组合神经激素阻断策略的估计方向有利但不精确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Left ventricular assist device (LVAD) support has been shown to induce the reversal of neurohormonal changes and myocardial recovery. This study aimed to evaluate the prevalence, predictors, and clinical impact of left ventricular (LV) recovery after LVAD implantation using data from the European Registry for Patients with Mechanical Circulatory Support. METHODS: Patients with at least one available left ventricular ejection fraction (LVEF) measurement at both baseline and post-LVAD implantation were enrolled. Left ventricular recovery was classified as 'no recovery' if LVEF increase was <5%, 'mild' if LVEF increased by 5%-15% with peak LVEF <50%, 'intermediate' if LVEF increased by >15% with peak LVEF <50%, and 'full' if LVEF increased by ≥5% with peak LVEF ≥50%. RESULTS: A total of 1550 patients with a median age of 57 (48-64) years were included. LV recovery occurred mostly within the first year, with marginal probabilities of no, mild, intermediate, and full recovery at 4 years being 51% [95% confidence interval (CI) 48-54%), 41% (95% CI 38-43%), 8% (95% CI 7-9%), and 1% (95% CI 0-1%), respectively]. INTERMACS Classes 2, 3, and 4 [compared with Class 1; hazard ratio (HR) .72, .64, and .51, respectively] were associated with a lower hazard of attaining any LV recovery, whereas renin-angiotensin system inhibitor use was associated with a higher hazard of attaining any LV recovery (HR 1.17; 95% CI 1.00-1.37). Each 10% higher LVEF value during follow-up was associated with an estimated 14% lower instantaneous hazard of all-cause mortality (HR .86; 95% credible interval .75-.98). The cumulative incidence of the composite major adverse cardiovascular event endpoint, including cardiovascular death, late right heart failure, and arrhythmia beyond the first year, was lower across higher LV recovery categories defined according to the LVEF value at 1 year (Gray's test, P = .042). CONCLUSIONS: This multicentre European study shows that LV recovery mostly occurs within the first year after LVAD implantation and is associated with better clinical outcomes. Renin-angiotensin system inhibitor use was associated with both any and intermediate/full LV recovery, while combination neurohormonal blockade strategies yielded directionally favourable but imprecise estimates, warranting further study during LVAD support.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Sener YZ, Jahangiri P, Veen K, et al. Left ventricular recovery and outcomes in patients with a durable left ventricular assist device: the EUROMACS registry. Eur Heart J. 2026. PMID: 42424031. doi:10.1093/eurheartj/ehag477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。